Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01446991 | Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy | completed | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03540407 | Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | completed | Phase 2 | 66 | Catalysis SLINDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT01065441 |
| Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer |
| completed |
| Phase 1 / Phase 2 |
| 9 |
| Michael Har-NoyINDUSTRY |
| 1 |
| Jan 22, 2020 |
| clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT03166891 | Phase Ib Study of Chiauranib in Patients With Ovarian Cancer | completed | Phase 1 / Phase 2 | 25 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00002602 | Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 1 / Phase 2 | 1,084 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 10, 2020 | clinicaltrials |
| NCT02830880 | FACBC Prostate Therapy Response | completed | Phase 2 | 7 | Emory UniversityOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03191968 | Prostate Cancer Survivors and Exercise and Behavioral Counseling(BOOST) | completed | Phase 2 | 27 | University of Illinois at Urbana-ChampaignOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02344017 | Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer(DUALIDES) | completed | Phase 1 / Phase 2 | 23 | Orion Corporation, Orion PharmaINDUSTRY | 4 | Dec 19, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT00479817 | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 161 | AmgenINDUSTRY | 0 | Dec 18, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT00003238 | Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00022412 | Doxercalciferol Before Surgery in Treating Localized Prostate Cancer | completed | Phase 2 | 60 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01946165 | Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | completed | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT02726113 | Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy | completed | Phase 2 | 50 | Medical University of South CarolinaOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02918357 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence(PSMA BCR) | completed | Phase 2 / Phase 3 | 385 | University of California, San FranciscoOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT01444924 | Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery | completed | Phase 2 | 75 | University of Wisconsin, MadisonOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00582556 | Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy | completed | Phase 2 | 44 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00214097 | Phase I/II Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 347 | University of Wisconsin, MadisonOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00849121 | Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 17 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00488982 | Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 125 | University of California, San FranciscoOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00445887 | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer | completed | Phase 2 | 60 | Gynecologic Oncology GroupNETWORK | 1 | Nov 19, 2019 | clinicaltrials |
| NCT03365297 | Therapeutics in Active Prostate Cancer Surveillance(TAPS01) | completed | Phase 2 | 11 | CCTU- Cancer ThemeOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00106418 | A Research Study for Patients With Prostate Cancer | completed | Phase 2 | 35 | CelgeneINDUSTRY | 0 | Nov 18, 2019 | clinicaltrials |
| NCT00030602 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 0 | Nov 5, 2019 | clinicaltrials |
| NCT00003400 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 45 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00005028 | Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 46 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00456989 | Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 39 | University of LouisvilleOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT03452982 | Sentinel Lymph Node in Early Ovarian Cancer(SENTOV) | completed | Phase 2 | 20 | Instituto de Investigacion Sanitaria La FeOTHER | 1 | Oct 18, 2019 | clinicaltrials |
| NCT00003413 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | completed | Phase 2 | 32 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01146340 | Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer(PHART6) | completed | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01248962 | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 2 | 146 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01585246 | Saw Palmetto: Symptom Management for Men During Radiation Therapy | completed | Phase 1 / Phase 2 | 48 | Michigan State UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT00721162 | Study of Ramucirumab in Ovarian Cancer | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 297 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02537444 | Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT01204710 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | completed | Phase 2 | 123 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 20, 2019 | clinicaltrials |
| NCT01802320 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01987999 | Eradication of Prostate Cancer Using F-989 | completed | Phase 2 | 60 | Optimal Health ResearchOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02849340 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02849353 | Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00831792 | TKI258 in Castrate Resistant Prostate Cancer | completed | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02279862 | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 9 | Aug 28, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2020source: clinicaltrials